CAJ | 학술논문

目的：探讨索拉非尼联合肝动脉化疗栓塞术（TACE）治疗肝癌的效果及安全性。方法回顾性分析37例系统服用索拉非尼的肝癌患者的临床资料，其中单药治疗者19例，联合 TACE 者18例。每2个月随访1次，主要观察两组肿瘤反应率及肿瘤无进展生存时间（PFS）。结果索拉非尼单药及联合 TACE 治疗组耐受性均良好，其常见副反应为乏力、手足综合征、贫血、腹泻等。单药治疗组患者完全缓解（CR）0例，部分缓解（PR）8例，疾病稳定（SD）9例，疾病进展（PD）2例；联合治疗组 CR 6例，PR 9例， SD 3例，PD 0例。联合治疗组的 PFS长于单药治疗组（ P ＜0．01）。结论索拉非尼联合 TACE治疗原发性肝癌耐受性良好，有效率较高，可延长患者 PFS。
목적：탐토색랍비니연합간동맥화료전새술（TACE）치료간암적효과급안전성。방법회고성분석37례계통복용색랍비니적간암환자적림상자료，기중단약치료자19례，연합 TACE 자18례。매2개월수방1차，주요관찰량조종류반응솔급종류무진전생존시간（PFS）。결과색랍비니단약급연합 TACE 치료조내수성균량호，기상견부반응위핍력、수족종합정、빈혈、복사등。단약치료조환자완전완해（CR）0례，부분완해（PR）8례，질병은정（SD）9례，질병진전（PD）2례；연합치료조 CR 6례，PR 9례， SD 3례，PD 0례。연합치료조적 PFS장우단약치료조（ P ＜0．01）。결론색랍비니연합 TACE치료원발성간암내수성량호，유효솔교고，가연장환자 PFS。
Objective To compare the efficacy and safety of sorafenib alone and in combination with transcatheter arterial che -moembolization (TACE) for hepatocellular carcinoma .Methods Clinical data of 37 hepatocellular carcinoma patients ,including 19 undergoing sorafenib monotherapy and18 undergoing sorafenib in combination with TACE ,were retrospectively analyzed.The subjects were followed up every two months .The primary study endpoint was tumor response rate and progression -free survival (PFS).Results The treatment of sorafenib and in combination with TACE group were well tolerated .The most common adverse events associated with sorafenib were asthenia,hand-foot skin reaction and diarrhea.In the sorafenib monotherapy group,no patients experienced a complete response ( CR),8 patients experienced a partial response (PR),9 patients had stable disease (SD),and 2 patients had progressive disease (PD).In combination group,6 achieved a CR,9 achieved a PR,3 had SD,and 0 had PD.The median PFS in the combination treatment group was obvious longer than that in monotherapy group ( P <0.01).Conclusion Sorafenib in combination with TACE are well tolerated and can increase the tumor response rate and prolong PFS in patients with hepatocellular carcinoma .